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Hypothyroidism is a condition where thyroid gland is not producing enough thyroid 
hormone, thyroxine, which regulates development, growth, and energy metabolism. The 
production of thyroxine is regulated by thyrotropin (TSH), a hormone secreted from the 
pituitary gland. TSH stimulates thyroid via thyrotropin receptor (TSHR). TSHR is a G-
protein-coupled receptor and the stimulation of the receptor activates different 
intracellular signaling pathways. The main signaling pathway in thyrocytes is Gs-
pathway, which stimulates the production of cyclic adenosine monophosphate (cAMP). 
G-proteins are composed out of α- and β-subunits. It is still not known how different G-
proteins effect to thyroid pathophysiology. The aim of the study is to investigate if 
deletion of thyroid specific Gs-protein α-subunit (Gαs) leads to hypothyroidism in a 
tamoxifen induced Gαs knock-out mouse model (iTGasKO). 
Genotyping of the mice was performed from DNA isolated from skin tissue. Serum 
TSH and thyroxin levels were measured from blood samples. cAMP, qPCR, 
histological and immunohistochemical experiments were done from thyroid tissue 
samples collected from the mice. The mice were weighted and measured every two 
weeks. EchoMRI was used to measure body composition and runners were used to 
measure the activity of the mice. Statistical analyses were done using Prism7 software.  
In general, iTGasKO mice were less active and in addition, weight loss and a lower 
amount of white adipose tissue were seen only in males. Unlike in human, in rodents it 
is typical to lose weight in hypothyroidism. In iTGasKO mice the serum thyroxine 
levels were lower and TSH levels higher compared to control mice (P<0.01) and cAMP 
production was decreased both in basal level and after stimulation (P<0.01). Gαs was 
expressed in small amounts in iTGasKO mice, but thyroid specific transcription factors 
and genes regulating thyroid hormone synthesis were downregulated. As an unexpected 
result, 6 months old iTGasKO mice were diagnosed to have papillary thyroid cancer-
like lesions in histopathological studies. These areas were also shown to express Gαs-
protein. This leads to conclusion of high TSH levels and partial Gαs expression leading 
to cancer-like lesions. This mouse model is a new way to show how TSHR’s Gs-
pathway knock-out leads to hypothyroidism. However, different species carry different 
signaling pathways, so the changes may not be identical in human pathophysiology. 
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The thyroid function is controlled by the thyroid-stimulating hormone (TSH), which 
binds to its G protein-coupled receptor (TSHR) on thyrocytes. TSHR can couple to all 
G protein families, but it mainly activates the Gs- and Gq/11-mediated signaling 
cascades. To date, there is still a knowledge gap concerning the role of the individual G 
protein cascades in thyroid pathophysiology and their putative clinical significance. 
Here, we demonstrate that the thyrocyte-specific deletion of Gαs in adult mice 
(iTGαsKO) rapidly impairs thyrocyte function and leads to hypothyroidism. 
Consequently, the iTGαsKO mice show reduced food intake, activity and altered brown 
adipose tissue histology. However, the body weight and the amount of white adipose 
tissue were decreased only in the iTGαsKO males. Unexpectedly, hyperplastic follicles 
and papillary thyroid cancer-like lesions with increased proliferation and slightly 
increased pERK1/2 staining were found in iTGαsKO mice at an older age. These 
tumors developed from nonrecombined thyrocytes still expressing Gαs in the presence 
of highly elevated serum TSH. In summary, we report that partial thyrocyte–specific 
Gαs deletion leads to hypothyroidism, but also to tumor development in thyrocytes with 
remaining Gαs expression. Thus, these mice are a novel model to elucidate the 





The thyroid gland produces and secretes thyroid hormones (TH), which play a 
fundamental role in vertebrate development, energy metabolism, thermogenesis and 
growth (1). The main regulator of the TH synthesis, growth and differentiation is the 
thyroid-stimulating hormone (TSH), which is secreted by the anterior pituitary. TSH 
binds to its G protein-coupled receptor (TSHR) expressed on the basolateral membrane 
of thyrocytes, and mainly activates the Gs/adenylate cyclase signaling. Activation of the 
Gs-pathway then leads to an increased production of intracellular cyclic adenosine 
monophosphate (cAMP) and the activation of various cellular functions in thyrocytes. 
However, TSHR can potentially couple to all four G protein families at least in vitro (2). 
Up to date, the physiological significance has primarily been demonstrated for the Gs- 
and Gq/11-mediated signaling pathways. However, but the detailed role of the different 
TSHR/G protein-coupling in thyroid pathophysiology is not known. In our previous 
study, we reported the importance of Gαq/11 for iodine organification, TH release and 
goiter growth in vivo (3). In patients with congenital hypothyroidism and nonclassical 
resistance to TSH, a TSHR mutation with a Gq/11-dominant coupling defect has been 
suggested to cause different phenotypes compared to TSHR mutations with impaired 
the Gs signaling (4,5). While the key role of Gs in TH synthesis, secretion, iodine 
uptake, and thyrocyte proliferation has been extensively investigated in vitro (6,7), an in 
vivo model has not been characterized so far.  
Gαs is a ubiquitously expressed G protein encoded by Gnas. Inactivation of the Gαs in 
an animal model (8) or loss of function mutations in humans leads to complex 
phenotypic manifestations, which are dependent on the genomic imprinting (9). The 
role of Gαs in thyroid tumor growth has been investigated in different cancer models, 
showing that the inactivation of Gs or TSHR signaling strongly attenuates tumor 
development (10,11). Furthermore, activating mutations in the Gαs or a constitutive 
activation of Gs-signaling pathway have been associated with hyperthyroidism and 
thyroid adenomas in mice (12,13). Analogously, activating mutations in Gαs or in the 
TSHR lead to constitutive receptor activation and cAMP production, which present 
well-known etiologies of hyperfunctioning thyroid adenomas (14–17). However, it 
remains unclear, whether the constitutive activation of Gs- or TSHR-mediated signaling 
alone triggers the expansion of the adenoma and development of thyroid cancer. 
Alternatively, it may simply promote the tumor growth after genetic alterations in 
oncogenes (18) or other genes (19). A clinical association between elevated serum TSH 
levels and a higher risk of thyroid malignancies has been reported (20). Moreover, the 
treatment with supraphysiological doses of thyroxine is recommended to suppress 
serum TSH, and to reduce the risk of a recurrent malignancy in patients with high risk 
thyroid cancer (21).  
Inactivating TSHR mutations (22) or the complete absence of TSHR (23) lead to 
hypothyroidism. Depending on the age of initiation and the duration of hypothyroidism, 
it may have a deleterious impact on the development and growth. In addition, to these 
genetic models presenting with severe congenital forms of hypothyroidism, 
pharmacologically induced hypothyroidism models have been commonly studied (24). 
However, the latter model used anti-thyroid drugs (methimazole or propylthiouracil), 
which inhibit the TH synthesis with possible side effects. To study the development of 
hypothyroidism and Gαs-mediated signaling in the thyroid, we generated thyrocyte-
specific tamoxifen-inducible Gαs deficient (iTGαsKO) mice. Here, we demonstrate that 
the genetic ablation of Gαs leads to rapid onset hypothyroidism and consequent sex-
dependent metabolic alterations, but also unexpectedly, to the development of papillary 




Generation of thyrocyte-specific tamoxifen-inducible Gαs -deficient mice 
Inducible thyrocyte-specific Gαs-deficient mice (iTGαsKO) were generated by crossing 
the mouse line expressing the tamoxifen-inducible Cre-recombinase under the control of 
the thyroglobulin promoter (25) with mice carrying loxP sites flanking exon 1 of the 
Gnas gene (26) (Fig. 1A). Cre-mediated thyrocyte-specific recombination was 
confirmed by PCR with genomic DNA, which showed the presence of the recombined 
allele after tamoxifen treatment. A weak PCR product of the recombined allele was also 
detected in non-treated Cre-positive Gnas floxed animals, indicating a low Cre-
mediated recombination activity in the absence of tamoxifen (Fig. 1B). The thyrocyte-
specific Gαs deficiency was also confirmed in primary cells, in which thyrocytes from 
iTGαsKO mice showed a significantly lower basal cAMP production and an 
approximately five times lower cAMP response to high dose (10 mIU) TSH stimulation 
compared to tamoxifen treated controls (Fig. 1C). Furthermore, strong Gαs staining was 
detected in the thyrocytes, of control mice, but only a weak staining was observed in the 
thyroids of iTGαsKO mice (Fig. 1D). Taken together, these results indicate that Gs 
signaling is strongly reduced, but not completely absent in the thyroids of iTGαsKO 
mice. 
 
The thyrocyte-specific deletion of the Gαs leads to a rapid onset of hypothyroidism 
The tamoxifen-induced recombination was induced at 4 weeks of age. The thyroid 
function tests (TFT), thyroid and pituitary weights were then assessed at two and six 
months of age. Severe hypothyroidism developed already one month after the induction, 
as demonstrated by highly elevated serum TSH and strongly decreased total T4 levels in 
both female and male iTGαsKO compared to control mice (Fig. 2A, B). Despite the 
detection of the recombined allele by PCR in the vehicle treated controls (Cre+/-, 
Gαsfl/fl), no significant difference in TSH or total T4 concentrations was observed 
between the control groups (Supplementary fig. 1A-D). This indicates that a small rate 
of Cre-mediated recombination without tamoxifen-induction did not physiologically 
affect TFTs in this model. In hypothyroid iTGαsKO mice, serum TSH levels were up to 
150-times higher at two and six months of age than in controls (Fig. 2A, B). In addition 
to hypothyroidism, thyroid weights in both genders of the 2- and 6- month old 
iTGαsKO mice were significantly decreased compared to controls (Fig. 2C). 
Furthermore, in line with the highly elevated serum TSH levels in iTGαsKO mice, the 
pituitaries of both males and females were significantly larger than in the control 
animals (Fig. 2D). 
The consequences of hypothyroidism were monitored by following the body weight and 
growth after tamoxifen induction. The body weights of the iTGαsKO males were 
significantly reduced at the age of 8 weeks compared to their control littermates (Fig. 
3A). Later the iTGαsKO males were approximately 15% leaner than the controls after 
six months. Interestingly, there was no significant difference in body weight in female 
iTGαsKO mice versus controls despite the similarly elevated serum TSH and decreased 
total T4 levels, reduced food consumption and body temperature (Fig. 3B) in the male 
and female iTGαsKO. This was accompanied with a reduced amount of total adipose 
tissue mass, estimated with the EchoMRI quantification (Fig. 3C, left), and smaller 
white adipose tissue fat pads (Fig. 3C, right). Nevertheless, the overall histology of the 
white adipose tissue was not altered (Supplementary fig. 2A). The adipocytes of the 
brown adipose tissue in iTGαsKO mice contained predominantly smaller lipid droplets 
compared to controls (Supplementary fig. 2B). Furthermore, the running wheel activity 
during the dark cycle was generally lower in both male and female iTGαsKO than in 
controls (Fig. 3D). There was no significant change in the growth velocity monitored by 
repeated tail length measurements (Supplementary fig. 1E, F).  
Thyroid histology, morphometric analysis, and gene expression 
As expected, most of the thyrocytes in iTGαsKO mice showed a weak Gαs staining one 
month after the induction of the Gαs deletion. The thyroid histology showed thinner 
thyrocytes and reduced follicle area in the iTGαsKO mice compared to controls (Fig. 1 
and 4A-F). At 2 months of age, the thyrocyte proliferation rate, indicated by the Ki67 
positive cells, was low and comparable between iTGαsKO and controls (Supplementary 
fig. 2C). Furthermore, the expression of thyrocyte-specific transcription factors and 
genes regulating TH synthesis were downregulated in both male and female KO 
compared to controls. In general, the downregulation was stronger in thyroids from 
iTGαsKO males (Fig. 4G), in which specifically the expressions of Hhex, Pax8, Tg, 
Tpo, Nis and Dio1 were significantly reduced. Similar, but less pronounced 
downregulation of Hhex, Nkx2.1, Tg, Dio1 gene expression was measured in iTGαsKO 
females (Fig. 4H). No changes in thyroidal gene expression of the genes related with 
oxidative stress were observed between iTGαsKO and controls (Fig. 4G, H). In line 
with the reduced gene expression of Nkx2.1, immunohistochemical staining with anti-
Nkx2.1 antibody presented weaker staining in iTGαsKO mice thyroids versus controls 
(Supplementary fig. 2D). 
 
The partial thyroid-specific Gαs deletion leads to the development of hyperplastic 
follicles and PTC-like lesions in areas with residual Gαs immunostaining 
The long-term impact of the Gαs deletion on thyroid histology was evaluated at six 
months of age. Interestingly, although the thyroid weights in iTGαsKO were not 
increased and a large part of the thyrocytes remained thin, several hyperplastic and 
neoplastic lesions were observed in all 6-month-old iTGαsKO thyroids of both sexes. 
The detailed analysis of these neoplastic lesions presented several typical features of 
papillary thyroid carcinomas, such as overlapping nuclei, nuclei with grooves, and 
nuclear enlargement (Fig. 5). Overall these neoplastic lesions covered up to 6% of the 
thyroid sections analyzed (with a range 1-6% of the total section area, n = 5 iTGαsKO 
mice, 4 sections/thyroid) (Fig. 5). Furthermore, strong Gαs staining in these altered 
areas was observed using the anti-Gαs antibody, indicating an incomplete deletion of 
the Gαs-protein in these thyrocytes (Fig. 6A). Moreover, the neoplastic areas were 
positive for Nkx2.1 and also strongly stained with the proliferation marker Ki67 (Fig. 
6B, C). The TSH-mediated activation of extracellular signal-regulated protein kinases 1 
and 2 (ERK1/2) was studied by immunohistochemistry using total-ERK1/2 (tERK1/2) 
and phospho-ERK1/2 (pERK1/2) antibodies. No changes in tERK1/2 staining were 
observed between Ctrl and KO thyroids (Fig. 6D). Interestingly, slightly increased 
pERK1/2 staining was detected in the hyperplastic and neoplastic areas of the 
iTGαsKO, whereas only a few thyrocytes were stained positive for pERK1/2 in the 
control thyroids (Fig. 6D, E).  
To test if the PTC-like lesions found in iTGαsKO thyroids harbored any known 
common genetic mutations corresponding to the human hotspot area in BRAF (c.1799 
c>t, V600E), genomic DNA from the microdissected neoplastic areas was isolated and 
sequenced. However, no mutations were found in seven microdissected tumor lesions 







The TSH mediated Gs/cAMP/PKA signaling is the main regulator of thyrocyte growth 
and differentiation. The constitutive activation of this signaling pathway can lead to the 
development of autonomously functioning adenomas (17,27). Furthermore, increased 
levels of TSH together with the genetic alterations in known oncogenes (28) or other 
genes (19) can promote tumor growth. However, it has been unclear, whether the 
constitutive activation of GNAS or TSHR mediated signaling alone can trigger the 
expansion of the adenoma and the development of thyroid cancer. Here, we demonstrate 
that a partial inactivation of Gαs/cAMP-mediated signaling in thyroids of adult mice 
impairs TH production and causes rapid onset hypothyroidism. However, in parallel, 
chronically highly elevated TSH together with the remaining of Gαs in a small 
percentage of the thyrocytes lead to the development of PTC-like lesions in these mice. 
This was an unexpected finding, as a spontaneous development of PTCs in hot thyroid 
nodules without alterations in oncogenes has been only very rarely observed (11,29–
32). Also, in rodents, the prolonged administration of anti-thyroid drugs and 
simultaneous TSH stimulation is primarily associated with the development of benign 
tumors and very rarely with thyroid cancer (33).  
Our data support previous epidemiological studies, which suggest an association 
between elevated TSH levels and an increased risk of developing thyroid cancer 
(34,35). In our model, the Gαs protein and the overall TSH-stimulated cAMP response 
is strongly reduced one month after the genetic deletion of the Gnas exon 1 in adult 
mice, leading to the downregulation of several TSH responsive genes and highly 
elevated serum TSH levels. At this early time-point, no altered areas in thyroid were 
observed. However, thyroid hyperplasia and PTC-like lesions were detected in six-
month-old iTGαsKO mice. The presence of strong Gαs staining in all hyperplastic and 
PTC-like areas suggests that the tumors originate from the non-recombined thyrocytes 
expressing the intact Gαs. Based on this data, Gαs is required for tumor development. 
However, also the Gα q/11 and other TSH mediated signaling pathways are activated 
due to very high serum TSH levels, which could contribute to promoting tumorigenesis. 
In contrast to iTGαsKO mice, mice lacking Gαq/11 in the thyrocytes show no tumors or 
goiter development despite highly elevated TSH levels and intact cAMP signaling (3). 
This suggest that the simultaneous activation of both Gαq/11 and Gαs pathways are 
required for the PTC-like phenotype. Similarly, in the thyroid-specific Braf (V600E) 
mouse model, which develop aggressive PTCs, the Gαs deletion attenuated, but did not 
prevent the development of PTC, suggesting that multiple pathways are involved (36). 
The increased pERK1/2 staining in the hyperplastic and PTC-like areas in iTGαsKO 
thyroids indicate that the activation of MAPK signaling pathway in these lesions 
requires Gαs. This is in line with in vitro studies describing that TSH and/or cAMP can 
augment the growth-factor stimulated pERK1/2 phosphorylation (7,37). However, the 
highly elevated TSH concentration alone in a mouse goiter model does not lead to an 
increased phosphorylation of ERK1/2 or CREB (38). Thus, additional events are needed 
for PTCs to occur. The requirement of TSHR signaling in BRAFV600E induced PTC 
(36) or other thyroid cancer mouse models (11,39) has been reported in several studies. 
Furthermore, it has been demonstrated that TSH may trigger advanced clinical stage of 
tumor, extrathyroidal extension, lymph node metastasis, genomic instability, or endure 
the oncogene induced senescence in the aforementioned mouse models (39,40). 
Nevertheless, the precise role of TSH in the etiology of PTC still remains unraveled. In 
humans, autonomously functioning thyroid adenomas are almost always benign (30,31). 
Moreover, there is no evidence of a gradual adenoma–carcinoma transition leading to 
PTC. In PTC, especially the activation of the MAPK signaling pathway has been linked 
to malignant thyroid growth. Moreover, mutations in oncogenes like BRAF (V600E) 
are frequently found in PTC (18). However, in our iTGαsKO model, no mutations in 
Braf hotspot area in the thyroid tumors were found suggesting other mechanisms play a 
role in the activation of this pathway. 
Despite the presence of Gαs, highly elevated TSH levels and hyperplastic and tumorous 
lesions in the thyroid of iTGαsKO mice, hypothyroidism persisted at least five months 
after the induction of the genetic Gαs deletion. This indicates that this relatively small 
part of the hyperplastic or PTC areas is insufficient to compensate the deficient TH 
synthesis. However, a longer follow-up is necessary to reveal whether the growth of 
these lesions would lead to increased serum TH concentration.  
In our study, the thyrocyte-specific inactivation of Gαs in adult mice lead to severe 
acute hypothyroidism. To the best of our knowledge, this represents the first inducible 
hypothyroidism mouse model in which hypothyroidism is induced in adult mice via 
thyroid-specific gene deletion. Therefore, our mouse line might differ from the previous 
congenital or pharmacologically induced hypothyroidism models (23). In both sexes of 
the Gαs deficient mice, the serum TSH levels were highly elevated and T4 levels were 
below the normal range already at one month after tamoxifen induction. This confirms 
that the Gs-mediated TH synthesis cannot be compensated by other TSH-activated 
signaling pathways despite the highly elevated serum TSH levels in the iTGαsKO mice 
compared to control mice. This clearly differs from the thyroid-specific Gαq/11-
deficient mice, which develop subclinical hypothyroidism a few months after the 
Gαq/11-deletion (3). Furthermore, a clear physiological sex-difference was observed in 
our hypothyroid model. The hypothyroid iTGαsKO males showed less weight gain 
associated with reduced total body fat, food intake, body temperature, and activity. In 
contrast, no weight difference was seen in hypothyroid iTGαsKO females compared to 
controls, despite of the similar degree of hypothyroidism, reduced food intake, body 
temperature and activity. Unlike in humans, where weight gain is a classical symptom 
of hypothyroidism, the weight loss has been reported when hypothyroidism is induced 
pharmacologically in rodents (41). The reason for the different adaptation of body 
weight in hypothyroidism between male and female iTGαsKO mice remains unclear, 
but it may reflect e.g. sex-specific differences in tissue deiodinase activities as 
suggested previously (42). Additionally, TH stimulate growth hormone secretion in 
rodents, which could partly explain the impaired growth and weight gain in hypothyroid 
rodent models (43).  
In conclusion, we demonstrate the essential role of Gαs in TH synthesis in vivo. 
Furthermore, we report that chronically elevated TSH can lead to the development of 
PTC-like lesions in the absence of known oncogenic alterations in mice. This model is a 
powerful tool to study adaptation mechanisms in hypothyroidism and detailed signaling 
pathways in TSH/Gs-mediated tumor development. 
 
 
MATERIALS AND METHODS 
Mouse model generation, husbandry and genotyping 
Thyrocyte-specific Gαs-deficient mice were generated by crossing the mouse line 
expressing the tamoxifen-inducible Cre recombinase under the control of the 
thyroglobulin promoter (25) with mice carrying a floxed allele of Gnas exon 1 (26) (Fig. 
1A). The control mice were tamoxifen (Tam) treated Cre-/-, Gαsfl/fl mice unless 
otherwise stated. The tamoxifen–inducible Cre mice had C57Bl/6N background, and the 
Gαs floxed mice had a mixed genetic background (26). The analysis was done for F3-F4 
generation. The animals were housed at the Central Animal Laboratory, University of 
Turku, under controlled conditions (12h light, 12h dark, 21±1°C) and ad libitum access 
to water and pelleted chow RM3 (E) Soya Free, Special Diet Services, Essex, UK) 
containing 1.6 μg/kg of iodine.  
Tamoxifen (Sigma Aldrich, MO, USA) was dissolved in 99.6% pure ethanol in a 
concentration of 100 mg/ml, aliquoted and stored in -20oC. Before injection, tamoxifen 
solution was thawed, gently heated and diluted in commercially available rapeseed oil 
(1:10). The KO (Cre+/- Tam) and the tamoxifen control (Cre-/- Tam) group of mice at 
the age of 4 weeks were injected ip with 1 mg (100 ul) of freshly prepared tamoxifen 
solution (5 mg/mouse). Cre controls (Cre+/- Veh) and vehicle controls (Cre-/- Veh) at 
the age of 4 weeks were injected with 100 ul of 99, 6% ethanol diluted 1:10 with 
rapeseed oil.  
 
Serum TSH and thyroid hormone measurements 
After tamoxifen injection, total T4 was measured every 4 weeks from mice from all 
groups (n=5 per group) for 5 months using total T4 kit ELISA kit (NovaTec, Germany) 
according to the manufacture’s protocol. Absorbance was measured at 450 nm with 
Wallac 1420 Victor2 plate reader (Perkin Elmer, MA, USA) and total T4 concentration 
was calculated with MultiCalc 200 software. Serum TSH was measured with Mouse 
Pituitary Magnetic Bead Panel (Merck Millipore, Germany). Fluorescent intensity was 
measured with the Luminex 200 (Austin, TX, USA) and data were calculated with the 
Luminex Xponent software v. 3.1. 
 
Primary cell culture and cAMP measurements 
After two months of tamoxifen injection (3 months of age), thyroid follicles were 
isolated and thyrocytes grown as described previously Jeker et al. (44), with minor 
modifications. Briefly, thyroids were dissected and placed into sterile DMEM media 
(Sigma-Aldrich, MO, USA) with 10% FCS (Biowest, Nuaillé, France) and cut into 
smaller pieces with a scalpel and subsequently digested with 225 U/ml Collagenase and 
75 U/ml Hyaluronidase (Stemcell Technologies, Canada) and 3 U/ml Dispase (BD 
biosciences, San Jose, CA) for 30 min at 37 C on a sample mixer. After digestion, the 
samples were centrifuged at 1500 rpm for 5 min, then washed with PBS. The follicles 
were resuspended in DMEM media containing 10% FCS and complemented with 10 
µg/ml of insulin, 5 µg/ml of transferrin, 3.5 ng/ml of hydrocortisone, 10 ng/ml 
somatostatin and 2 ng/ml Gly-His-Lys acetate (Sigma-Aldrich, MO, USA) on a 96-well 
plate. After 3-4 days in cell culture, the cells were washed three times with PBS and 200 
μl of fresh cell culture media without serum and hormones was added, containing 1 mM 
3-Isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich, MO, USA). The cells were 
stimulated with 1 and 10 mU/ml of bTSH (Sigma-Aldrich, MO, USA) for 1h and the 
media containing extracellular cAMP were collected from the wells. Intracellular cAMP 
was extracted by incubating the cells for 30 min with 0.1 M HCl on ice. Extra- and 
intracellular cAMP, was measured with radioimmunoassay (RIA) as previously 
described (45).  
 
Quantitative Real-Time PCR (qRT-PCR) 
Samples were snap frozen in liquid nitrogen and stored at -88 oC. Samples were 
homogenized by using stainless metal beads (QIAGEN, Germany) at 50 rpm for 2 min. 
Total RNA was isolated with TRIsure™ reagent (Bioline, UK) according to the 
manufacture’s protocol. RNA concentration and purity was measured with NanoDrop™ 
ND-1000 (Thermo Scientific, MA, USA) UV-VIS spectrophotometer at 260/280 and 
260/230 nm. Furthermore, RNA integrity was evaluated in 1% agarose gel and 
visualized with Midori Green Direct reagent (Nippon Genetics, Japan). RNA (500 μg) 
was treated with DNase I amplification grade (Sigma Aldrich, MO, USA) and 
transcribed to cDNA by using SensiFAST™ cDNA Synthesis Kit (Bioline, UK) 
according to the manufacture’s manual. Then cDNA was diluted 1:100 in Braun sterile 
water (Braun, Germany) and qRT-PCR was performed in 10 μl reaction volume using 
SYBR Green PCR Master Mix (Applied Biosystems, CA, USA) accordingly to 
manufacture’s protocol. Samples were normalized to the geometric mean of the 
Cyclophilin A (Ppia) and the Ribosomal protein L19 (Rpl19) expression. Efficiency of 
primer binding was established by using a standard curve made from pooled control 
samples in the following dilutions: 1:10, 1:100, 1:1 000 and 1:10 000. The final 
concentration of primers was 500 nM. Relative gene expression was calculated with the 
Pfaffl method. Relative gene expression from each group (n=5) was compared to the 
Cre-/- Tam control group (n=5). The list of used primers with temperatures of annealing 
is attached in the Table 1. 
 
Histology, immunohistochemistry and morphometric analysis 
Histology samples were fixed in 10% neutral buffered formaline (Oy FF-Chemicals Ab, 
Finland), dehydratated in 50 % EtOH for 1 h in RT, 70 % o/n in +4 oC and embedded in 
paraffin. Samples were cut with a microtome (Leica, Germany) into 4 m sections. 
Immuonohistochemistry and Hematoxylin-Eosin (HE) stainings were performed as 
described previously (46). The thickness of the thyrocytes and the follicle area were 
calculated with Panoramic Viewer software v. 1.15.4 (3DHistech Ltd., Hungary. The 
list of used antibodies is attached in the Table 2.   
 
Papillary thyroid cancer-like (PTC-like) classification and genotyping 
Formalin-fixed paraffin-embedded mouse thyroids were cut by using a microtome 
(Leica, Germany) into 4 μm section on membrane slides 1.0 PEN (Carl Zeiss, 
Germany). Slides were deparaffinized with xylene and stained for 30 second with 
Mayer’s hematoxylin with standard procedure. Pictures at 50x magnification of whole 
thyroids were taken by using Leica DMRBE microscope (Leica, Germany). The lesion 
was classified as PTC-like when one or more of the following PTC features were 
observed: overlapping nuclei, nuclei with grooves, or pseudoinclusions. Selected PTC-
like lesions were cut with a PALM MicroBeam (Carl Zeiss, Germany) laser capture 
microscope. DNA was extracted by using an in-house isolation method (protocol on 
request). PCR was performed for mouse Braf (codon 600). PCR products were 
separated in 1.5 % standard agarose gel for 30 minutes at 120 V in 1xTBS. PCR 
products were cutted from the gel and purified with the NucleoSpin Gel and PCR 
Clean-up kit (Macherey-Nagel, Germany) according to manufacturer’s protocol. 
Purified products were sequenced (GATC Biotech AG, Germany) and analyzed for 
plausible hot-spot mutations with FinchTV 1.4.0 software (PerkinElmer, Finland). The 
sequence for the BRAF (c.1799 c>t, V600E) genotyping primers were as follow: F: 5’-
TTCATGAAGACCTCACGGTAAAA-3’ and R: 5’-
GTGAGTAGTGGGAACTGTGAAAG - 3’. 
 
Growth, bodyweight, temperature and body composition  
Body weight and tail length of mice from each group (n≥5) were followed-up for 5 
months every two weeks after tamoxifen induction. Body composition of the mice at the 
age of 6 months were measured with a body composition analyzer based on quantitative 
nuclear magnetic resonance (Echo MRI-700, EchoMRI Houston, TX, USA). Lean 
mass, fat mass and total water was adjusted to the weight of mice and percentage value 
was calculated. 
 For measuring food consumption, mice (n = 9/group) at the age of 7 weeks were 
divided one week before into groups of 2-3 animals per cage. The provided food was 
weighed before and after four days. Body temperature was measured with a rectal probe 
(Physitemp instruments Inc,, NJ, USA). At the age of 8 weeks, mice (n= 6-9 per group) 
were single caged, and after 48 hours of adaptation, measurement of activity was 
carried-out for the next 72h using wireless running wheels ENV-047 (MedAssociates 
Inc, USA). Counts from each hour were summed up and statistica was performed for 
total counts from each 3 days for each group of mice. 
 
Statistical analysis 
Statistical analyses were performed with two-tailed Student´s t-test for samples with 
homogenous variances with CI=95%. For samples with non-homogenous variances, 
non-parameteric Mann-Whitney's U test was applied. For more than one analyzed 
group, One-Way Analysis of Variance (ANOVA) with Duncan´s post-hoc test was 
used. All statistical calculations and graphs were made by using GraphPad Prism 7 
software (GraphPad Software Inc., CA, USA). Levels for significances were as 
following: * P<0.05, ** P<0.01, *** P<0.001.  
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Figure 1: Generation and validation of the tamoxifen-inducible thyrocyte-specific Gαs-deficient 
(iTGαsKO) mice. A) Outline of the generation strategy of the iTGαsKO mouse line. (F = (forward), R = 
(reverse) and Null - genotyping primers, WT – wild type (330 bp); iTGαsE1 (fl/fl) – Gαs Exon 1 floxed 
(fl/fl) homozygous (390 bp); Cre+/- – Cre recombinase expressing heterozygous mouse under thyroglobulin 
(Tg) promoter; iTGαsKO – thyrocyte-specific tamoxifen-inducible homozygously Gαs-deficient mouse 
(250 bp).  B) Analysis of the recombination by PCR using genomic DNA. fl/fl – LoxP floxed homozygous; 
fl/- – LoxP floxed heterozygous; -/- – wild type; +/- – Cre recombinase heterozygous; Tam- – vehicle 
treated; Tam+ – tamoxifen treated mouse. C) cAMP measurements of the basal and TSH-stimulated 
primary thyrocytes of the control and iTGαsKO mice. ** = P<0.01. D) Immunohistochemical analysis of 
the control (Ctrl) and iTGαsKO (KO) thyroids using anti-Gαs antibody. Small picture: negative control 






Figure 2: Thyroid function test, thyroid and pituitary weights in the iTGαsKO and control animals. 
A) serum TSH, B) total T4 concentrations, C) thyroid and D) pituitary weights in 2 and 6 months old control 
and iTGαsKO mice. Ctrl – control mice (Cre-/-, Gαsfl/fl, Tam); KO - iTGαsKO mice (Cre+/-, Gαsfl/fl, Tam); 
Dotted line – assay detection limit; Whiskers show minimum and maximum value, lower box line: 25th 





Figure 3: Metabolic consequences of the hypothyroidism in the iTGαsKO mice. A) Body weight of the 
iTGαsKO mice and controls at age of 5-20 weeks (n = 9/group). Ctrl – control mice (Cre-/- Tam); KO - 
iTGαsKO mice (Cre+/- Tam). B) Food consumption (left) and body temperature (right) of the 2 months old 
iTGαsKO mice and controls. C) EchoMRI measurement of mass percentage (left) and picture of total 
adipose tissue (right) of 6 month old iTGαsKO mice. D) Activity of 2 months old iTGαsKO mice and 
controls. Grey background – night cycle. Ctrl – control mice (Cre-/-, Gαsfl/fl, Tam); KO - iTGαsKO mice 
(Cre+/-, Gαsfl/fl, Tam); Whiskers show minimum and maximum value, lower box line: 25th percentile; middle 
box line: median; upper box line: 75th percentile; * = P <0.05; ** = P<0.01.   
 
Figure 4: Thyroid histology, morphometric analysis and gene expression in the iTGαsKO mice.  
Histology (HE) of the control (A, C) and iTGαsKO (B, D) thyroids from 2- and 6-month-old animals, 
respectively. scale bar: 50 μm. Morphometric analysis of thyrocyte thickness (E) and follicles area (F) of 
controls and the iTGαsKO thyroids. Whiskers show minimum and maximum value, lower box line: 25th 
percentile; middle box line: median; upper box line: 75th percentile. Gene expression analysis of thyroid 
specific genes and genes involved in antioxidation in 6 months old iTGαsKO male (G) and female (H) 
thyroids. Ctrl – control mice (Cre-/-, Gαsfl/fl, Tam); KO - iTGαsKO mice (Cre+/-, Gαsfl/fl, Tam); Error bars 
show SEM value; * = P <0.05; ** = P<0.01; *** = P<0.001.  
 
Figure 5: Hyperplastic and papillary thyroid carcinoma-like (PTC-like) lesions in the 6 months old 
iTGαsKO mice.  A) HE staining of male iTGαsKO mouse thyroid, PTCs-like areas marked with dotted 
line B) and C) higher magnifications of the PTC-like lesions with the typical PTC features marked with 
symbols: capsule (blue arrow), elongated nuclei (yellow arrow), overlapping nuclei (green arrow), enlarged 
nuclei (red arrow) and grooves (black arrow).  
 
 
Figure 6: IHC analysis of 6 months old iTGαsKO thyroids with PTC-like areas. IHC stainings with 
antibodies against A) Gαs, B) Nkx2.1, C) Ki67, D) total-Erk1/2, E) phospho-Erk1/2. Antibodies used for 
the staining’s are listed in the Table 2. Ctrl – control mice (Cre-/-, Gαsfl/fl, Tam); KO - iTGαsKO mice (Cre+/-
, Gαsfl/fl, Tam); Scale bar: 50 μm. 
SUPPLEMENTARY FIGURES AND TABLES 
 
Supplementary figure 1: Characterization of all control groups. TSH concentration in A) 2 months and 
B) 6 months old control mice. Total T4 concentration in 8 - 24 weeks old control and iTGαsKO C) males 
and D) females. Tail length in 5 - 20 weeks old control and iTGαsKO E) males and F) females. Cre+/- – Cre 
recombinase expressing mouse; Cre-/- – Cre recombinase non-expressing mouse; Tam – tamoxifen treated 
mouse; Veh – vehicle treated mouse; KO - iTGαsKO mice; iTGαsKO group was compared with Tam control 
group; Error bars show SEM value; * = P <0.05; ** = P<0.01; *** = P<0.001.  
 
 
Supplementary figure 2: Adipose tissue characterization and thyroid proliferation analysis in the 
iTGαsKO mice. White (WAT) A) and Brown (BAT) B) adipose tissue in the 6 months old iTGαsKO mice. 
C) Ki67 and D) Nkx2.1 staining in the thyroid of 2 months old iTGαsKO mice. Ctrl – control mice (Cre-/-, 
Gαsfl/fl, Tam); KO - iTGαsKO mice (Cre+/-, Gαsfl/fl, Tam); Scale bar: 50 μm.  
 
 
Table 1: List of qRT-PCR primers 
Gene 
symbol 
Forward primer Reverse primer 
Tshr 5’- CCATCTCCTTCTATGCGCTGTCG - 3 
 
5’- GCTGAGCAGGATGAACACGTCC - 3 
 Foxe1 5’- GACTCTGGGCGGCATCTACAAGTT - 3 
 
5’- TTGAGGAAGCAGTCGTTGAGGGT - 3 
 
Hhex 5’- CGGACGGTGAACGACTACAC - 3 
 




5’- CCTGCTGAGTTCTCCATATTATTAC - 3 
 
5’- CCTTTGTGTGACTCTCTGGG - 3’ 
 
Nkx2.1 5’- CAGCCGACGCCGAATCAT - 3’ 
 
5’- CTGGCCCTGTCTGTACGC - 3’ 
 
Tg 5’- CTTATGGGAGGCTCTGCAC - 3’ 
 
5’- CACAGCCAGGAGCTTGGTC -3’ 
 
Tpo 5’- CAAAGGCTGGAACCCTAATTTCT - 3’  
 
5’- AACTTGAATGAGGTGCCTTGTCA - 3’ 
 
Nis 5’- GGGATGCACCAATGCCTCTG - 3’  
 
5’- GTAGCTGATGAGAGCACCACA - 3’ 
 
Dio1 5’- GGGCAGGATCTGCTACAAGG - 3 
 
5’- CGTGTCTAGGTGGAGTGCAA - 3 
 
Srxn1 5’- CCCAGGGTGGCGACTACTA - 3 
 
5’- GTGGACCTCACGAGCTTGG - 3 
 
Sod3 5’- CCTTCTTGTTCTACGGCTTGC - 3 
 
5’- TCGCCTATCTTCTCAACCAGG - 3 
 
Ppia 5’- CATCCTAAAGCATACAGGTCCTG - 3’ 
 
5’- TCCATGGCTTCCACAATGTT - 3’ 
 
Rpl19 5’- CTGAAGGTCAAAGGGAATGTG - 3’ 
 
5’- GGACAGAGTCTTGATGATCTC - 3’ 
 
 
Table 2: List of antibodies 
Antigen Isotype / Clonality 
(clone) 
Manufacture (Cat. No.) Dilution Application 
Gs Rabbit IgG / polyclonal 
(-) 
Abcam (83735) 1:150 IHC 







NKX2.1 Mouse / monoclonal 
(8G7G3/1) 
Dako (M3575) 1:200 IHC 
ERK1/2 Rabbit IgG / monoclonal 
(137F5) 





Rabbit IgG/ monoclonal 
(D13.14.4E) 
Cell signaling Technology, 
Inc (4370) 
1:400 IHC 
 
 
 
 
 
 
 
 
